Rochester Regional Health (USA), a $2.2 USD billion integrated health care delivery system with more than 17000 employees, has announced that its wholly-owned subsidiary, ACM Global Laboratories (USA), has added to its portfolio with the strategic acquisition of ABS Laboratories (UK) which is located outside of London and focused on bioanalytical services.
Headquartered in the United States, ACM Global Laboratories is one of the largest global independent laboratories in the industry, performing more than 30 million laboratory tests annually and employing scientists and support personnel in the Americas, Europe, Singapore, China and India.
As a GLP bioanalytical lab, ABS Laboratories specializes in complex assay method development and validation for the quantification of drugs, metabolites and biomarkers in biological samples for preclinical and clinical trials including final regulatory submission. The organization has significant experience in supporting pharmaceutical companies, academic institutions, and government agencies in the U.S. and U.K. that complements ACM’s growing portfolio.
ACM has grown significantly over its 40-year history, both organically and through acquisitions. This acquisition adds to its emergent collection of domestic and international laboratories focused on bioanalytical, toxicology and central lab testing. In late 2017, ACM added Philadelphia-based DrugScan, Inc. and DSI Medical Services, Inc. to its portfolio.
ACM Global Laboratories, an affiliate of Rochester Regional Health (New York, USA), is one of the largest global independent central labs in the industry. ACM is certified by the College of American Pathologists (CAP) and the Substance Abuse and Mental Health Services Administration (SAMHSA). The company delivers high-quality laboratory testing and diagnostic lab services in support of both clinical trials research, toxicology and individual patient care.
ABS Laboratories (UK) is a MHRA, GLP and GCP accredited contract research organisation that specialises in the quantification of drugs, metabolites and biomarkers in biological and non-biological samples.